Kelun-Biotech Achieves HKEX Milestone with "B" Marker Removal, Advances Global ADC Pipeline
核心洞察
Kelun-Biotech (搜索) received Hong Kong Stock Exchange approval to remove the "B" marker from its stock code, effective April 14, 2026, signifying achievement of higher operating standards.
The company has secured approvals for 4 products across 8 indications within three years of listing, with 3 products covering 5 indications included in China's National Reimbursement Drug List.
MSD is evaluating 17 global Phase III clinical trials for sacituzumab tirumotecan (sac-TMT), with multiple studies approaching data readout stages.
Sichuan Kelun-Biotech (搜索) Biopharmaceutical Co., Ltd. (6990.HK) announced that The Stock Exchange of Hong Kong Limited has approved the removal of the "B" marker from its stock code, effective April 14, 2026. The approval follows the company's application under Rule 18A.12 of the Listing Rules and represents satisfaction of higher operating standards, marking a new developmental phase for the biopharmaceutical company.
Accelerated Product Development and Market Access
Within three years since its public listing, Kelun-Biotech (搜索) has demonstrated significant execution capabilities by securing approvals for 4 products across 8 indications. Notably, 3 products with 5 indications have been included in China's National Reimbursement Drug List (NRDL), establishing what the company describes as a fully integrated platform spanning from R&D to commercialization.
The company's end-to-end drug development platform positions it to advance its pipeline addressing unmet medical needs in oncology and other major disease areas. This integrated approach has enabled the rapid transition from research and development to market access within a compressed timeframe.
Global Partnership Progress and Clinical Milestones
Kelun-Biotech (搜索) continues expanding its international presence through collaborations with leading pharmaceutical partners, including MSD and Crescent Biopharma. The partnership with MSD has resulted in the evaluation of 17 global Phase III clinical trials for sacituzumab tirumotecan (sac-TMT, 佳泰莱®), with multiple studies approaching the data readout stage.
These global development programs represent significant milestones in the company's strategy to advance relevant assets on an international scale. The extensive Phase III program for sac-TMT demonstrates the potential global impact of Kelun-Biotech (搜索)'s ADC technology platform.
Technology Platform Innovation
The company has established leading technology platforms in ADC and novel conjugation drugs, biologics, and small molecules, creating what it characterizes as a differentiated innovative pipeline. Sacituzumab tirumotecan has demonstrated strong worldwide competitiveness as a representative best-in-class (BIC) potential asset.
Beyond current BIC candidates, Kelun-Biotech (搜索) is advancing a portfolio of potential first-in-class (FIC) candidates that integrate new targets, new mechanisms, and new technologies. This approach aims to expand the boundaries of original innovation and strengthen long-term sustainable development.
The company's proprietary ADC and novel DC platforms, including OptiDC™, have yielded 2 ADC projects with 5 indications approved for marketing, with multiple ADC and novel DC assets in clinical or preclinical research stages.
Leadership Perspective and Future Outlook
Dr. Michael Ge, CEO of Kelun-Biotech (搜索), stated: "We are pleased that our company has met the relevant requirements under the HKEX Listing Rules and has successfully removed the 'B' marker from its stock code. This milestone reflects our strong capabilities in biopharmaceutical innovation and value realization."
The CEO emphasized that supported by a solid financial position, the company will continue to enrich its innovative and synergistic pipeline, accelerate product development, benefit a broader patient population and create long-term value for shareholders.
Currently, Kelun-Biotech (搜索) maintains more than 30 ongoing key innovative drug projects, with 4 projects covering 8 indications approved for marketing, 1 project in the NDA stage, and more than 10 projects in the clinical stage. The company focuses on major disease areas including solid tumors (搜索), autoimmune, and metabolic diseases (搜索) while establishing a globalized drug development and industrialization platform.